It is a single blind randomized symptom triggered study to assess efficacy and safety of
pregablin combined with the symptom triggered treatment for opiate withdrawal syndrome vs.
clonidne with the same with the symptom triggered treatment for opiate withdrawal syndrome.
Phase:
Phase 4
Details
Lead Sponsor:
St. Petersburg Bekhterev Research Psychoneurological Institute